Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Seitz, Stephan ^a   Buchholz, Stefan ^a   Schally, Andrew Victor ^b,c   Weber, Florian ^a   Klinkhammer Schalke, Monika ^d   Inwald, Elisabeth C ^a   Perez, Roberto ^b   Rick, Ferenc G ^e   Szalontay, Luca ^b   Hohla, Florian ^f   Segerer, Sabine ^g   Kwok, Chui Wai ^a   Ortmann, Olaf ^a   Engel, Jörg Bernhard ^h  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^f UNIVERSITY OF SALZBURG   (Austria)

^g ENDOKRINOLOGIKUM HAMBURG   (Germany)

^h JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

AEZS 108; AEZS 125; LHRH receptor; Targeted therapy; Triple negative breast cancer

Indexed keywords

AEZS 125; DISORAZOL Z; DOXORUBICIN; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; PLANT MEDICINAL PRODUCT; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ZOPTARELIN DOXORUBICIN; AEZS-125; ANTINEOPLASTIC AGENT; GONADORELIN; LHRH, LYSINE(6)-DOXORUBICIN; OXAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY ASSAY; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LHRH GENE; MDA MB 231 CELL LINE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; ANALOGS AND DERIVATIVES; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MICE; MICE, NUDE; OXAZOLES; RECEPTORS, LHRH; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924630979     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-847     Document Type: Article

References (30)

1. Fost C, Duwe F, Hellriegel M, Schweyer S, Emons G, Grundker C: Targeted chemotherapy for triple-negative breast cancers via LHRH receptor. Oncol Rep 2011, 25:1481-1487.
2. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13:2329-2334.
3. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434.
4. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007, 109:1721-1728.
5. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, Mitchell EP: Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's surveillance, epidemiology, and end results database. Cancer 2007, 110:876-884.
6. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer 2007, 109:25-32.
7. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006, 24:5652-5657.
8. Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD: Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007, 7:134.
9. Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Hölzel F, Schulz KD, Schally AV: High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 1993, 77:1458-1464.
10. Emons G, Schally AV: The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod 1994, 9:1364-1379.
11. Bajusz S, Csernus VJ, Janaky T, Bokser L, Fekete M, Schally AV: New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. Int J Pept Protein Res 1988, 32:425-435.
12. Rekasi Z, Czompoly T, Schally AV, Halmos G: Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci U S A 2000, 97:10561-10566.
13. Szepeshazi K, Halmos G, Schally AV, Arencibia JM, Groot K, Vadillo-Buenfil M, Rodriguez-Martin E: Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs. J Cancer Res Clin Oncol 1999, 125:444-452.
14. Halmos G, Schally AV, Kahan Z: Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix. Int J Oncol 2000, 17:367-373.
15. Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Hölzel F, Schulz KD, Schally AV: High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 1993, 53:5439-5446.
16. Limonta P, Pratesi G, Moretti RM, Montagnani Marelli M, Motta M, Dondi D: Comments on inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II, Jungwirth et al., Eur J Cancer 1997, 33 (7), 1141-1148. Eur J Cancer 1998, 34:1134-1136.
17. Schally AV, Comaru-Schally AM: Hypothalamic And Other Peptide Hormones. In Cancer Medicine. 5th edition. Edited by Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland RF, Frei E. Lewiston, NY: Decker; 2000:715-729.
18. Wormald PJ, Eidne KA, Millar RP: Gonadotropin-releasing hormone receptors in human pituitary: ligand structural requirements, molecular size, and cationic effects. J Clin Endocrinol Metab 1985, 61:1190-1194.
19. Engel JB, Schally AV: Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 2007, 3:157-167.
20. Engel JB, Schally AV, Dietl J, Rieger L, Honig A: Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Mol Pharm 2007, 4:652-658.
21. AicherTS B, Blumenstein L, Schubert A, Gründker C, Engel JB, Ortmann O, Mueller R, Guenther E, Gerlach M, Teifel M: LHRH receptor targeting as mechanism of anti-tumor activity for cytotoxic conjugates of Disorazol Z with the LHRH receptor agonistic peptide D-Lys6-LHRH AACR Annual Meeting, April 6 to 10. Wahingtom DC: 2013. Abstract Nr 5467, www.aacr.org.
22. Engel J, Emons G, Pinski J, Schally AV: AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors. Expert Opin Investig Drugs 2012, 21:891-899.
23. Fekete M, Wittliff JL, Schally AV: Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 1989, 3:137-147.
24. Bajo AM, Schally AV, Halmos G, Nagy A: Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Clin Cancer Res 2003, 9:3742-3748.
25. Schally AV, Nagy A: Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 2004, 15:300-310.
26. Buchholz S, Seitz S, Schally AV, Engel JB, Rick FG, Szalontay L, Hohla F, Krishan A, Papadia A, Gaiser T, Brockhoff G, Ortmann O, Diedrich K, Köster F: Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition. Int J Oncol 2009, 35:789-796.
27. Engel JB, Schally AV, Buchholz S, Seitz S, Emons G, Ortmann O: Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH). Arch Gynecol Obstet 2012, 286:437-442.
28. Emons G, Kaufmann M, Gorchev G, Tsekova V, Gründker C, Günthert AR, Hanker LC, Velikova M, Sindermann H, Engel J, Schally AV: Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. Gynecol Oncol 2010, 119(3):457-461.
29. Emons G, Gorchev G, Sehouli J, Wimberger P, Stähle A, Hanker L, Hilpert F, Sindermann H, Gründker C, Harter P: Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5). Gynecol Oncol 2014, 133(3):427-432.
30. Emons G, Gorchev G, Harter P, Wimberger P, Stähle A, Hanker L, Hilpert F, Beckmann MW, Dall P, Gründker C, Sindermann H, Sehouli J: Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5). Int Journal Gynecol Cancer 2014, 24(2):260-265.